Caribou Biosciences is shutting down remaining clinical development plans for two allogeneic CAR-T programs after failing to secure financing for its late-stage trial plans, according to company disclosures. The move ends vispa-cel development and shifts the company toward strategic alternatives. The same day, additional signals continued across the cell therapy landscape, including the broader operational uncertainty faced by companies scaling off-the-shelf approaches. Together with the Caribou decision, it illustrates how funding access can determine whether late-stage testing proceeds even when programs reach trial readiness. For investors and strategic partners, the implication is clear: platform promise is no longer sufficient without sustainable capital for manufacturing, registration, and trial completion.